Clinical studies and meta-analyses have further suggested that l-carnitine administration can significantly improve serum alanine transaminase (ALT) and aspartate transaminase (AST) levels as well as NAFLD activity scores in patients with MASH.10 Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.